Cut Out

Three months after getting a pharmaceutical whistleblower to the stand alive, Nora Harken is sitting in a stalled investigation.

The network that tried to kill her witness — a shadow operation called Blackvine — has gone dark. Eleven weeks without a signal. The financial trails end in dissolved shell companies and shuttered accounts. The DOJ task force Nora joined as a consultant has resources, clearance, and nothing to aim at. They can describe Blackvine. They can't reach it.

Then an old case surfaces: a defense contractor executive who died in a car accident in 2019. Single-vehicle. Rain-slick road. No witnesses. The investigation closed in two weeks. It has Blackvine's fingerprints on everything except the evidence.

Nora follows the thread — and what she finds isn't one murder. It's a pipeline. Assessment firms that identify vulnerable targets. Law firms that move money through layers of deniability. A network of former intelligence contractors who've turned corporate risk mitigation into an industry, with at least five clients across defense, energy, and pharmaceuticals. Every layer is insulated from the next. Every participant does exactly what they're hired to do and never looks past the boundary of their own work. That's the design. That's what makes it untouchable.

But the deeper Nora maps the architecture, the closer the lines converge on someone she knows — someone whose judgment she's trusted for twelve years, whose name keeps appearing in the spaces between the firms and the contracts and the deaths. And the answer to the question she's been asking since Ashland may be worse than the silence that preceded it.